Johnson & Johnson transitions Remicade® (infliximab) and Simponi® (golimumab) for treatment of patients with Inflammatory Diseases

Johnson & Johnson’s portfolio now includes treatment options for patients with rheumatoid arthritis, axial spondylarthritis, and polyarticular juvenile idiopathic arthritis.

High Wycombe, UK, 17 October 2024 - Johnson & Johnson (J&J) announced today that it has now assumed all sales, marketing and distribution responsibility for Remicade® (infliximab) and Simponi® (golimumab) in the United Kingdom (UK). Infliximab is an anti‑inflammatory medicine indicated for the treatment of rheumatoid arthritis (RA), Crohn’s disease (CD), paediatric CD, ulcerative colitis (UC), paediatric UC, radiographic axial spondyloarthritis (ankylosing spondylitis), psoriatic arthritis (PsA), and psoriasis.1 Golimumab is an anti-inflammatory medicine indicated for the treatment of RA, polyarticular juvenile idiopathic arthritis, PsA, radiographic axial spondyloarthritis (ankylosing spondylitis), non-radiographic axial spondyloarthritis, and UC.2 3

For more than 25 years, infliximab, and, for more than a decade, golimumab, have helped millions of people managing life-altering inflammatory diseases and remain significant options in the treatment paradigm for these people in the UK.2,4 The addition of infliximab and golimumab into J&J’s established immunology portfolio represents a significant milestone in the company’s ongoing commitment to provide trusted and reliable healthcare solutions for patients in need.

Merck Sharp & Dohme (UK) Limited (MSD) ceased the commercialisation of infliximab and golimumab and transferred the responsibility of Local Representative to Janssen-Cilag Ltd (a Johnson & Johnson Company) who assumed commercial activities from 1 October 2024. J&J collaborated closely with MSD during the transition process to prevent any impact to the lives of patients using infliximab and golimumab.

About Remicade (infliximab)

Infliximab 100 mg is a chimeric human-murine IgG1 monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of tumour necrosis factor alpha (TNFα) and inhibits its functional activity. TNFα is involved in inflammatory processes of the body so blocking it can reduce the inflammation in the body. Infliximab is usually used when other medicines or treatments have failed, in adults with the following diseases: rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. Infliximab is also used in patients aged between 6 and 17 years with severe, active Crohn’s disease or severely active ulcerative colitis, when they have not responded to or cannot take other medicines or treatments.1

About Simponi (golimumab)

Golimumab 50 mg / 100 mg is a human monoclonal antibody that forms high affinity, stable complexes with both the soluble and transmembrane bioactive forms of human TNFα, which prevents the binding of TNFα to its receptors. TNFα is involved in inflammatory processes of the body so blocking it can reduce the inflammation in the body. Golimumab is indicated for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, radiographic axial spondyloarthritis (ankylosing spondylitis), non-radiographic axial spondyloarthritis, and ulcerative colitis. 2, 3

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.janssen.com/UK/johnson-johnson-innovative-medicine. You can also follow us on LinkedIn. © Janssen-Cilag Limited, a Johnson & Johnson Company. All rights reserved.